Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years. A number of companies have already tried to develop inhaled insulin, including Pfizer Inc, whose product Exubera, was discontinued in 2007. This form of insulin has raised concerns that it could cause lung damage.